Amgen Inc. Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments
Amgen Inc. (AMGN) had Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments of $100.00 million as of 2017-12-31, per its 10-K filed 2018-02-13.
Discontinued › Notes › Fair Value Disclosures
us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments · last filed 2018-02-13
- 2017-12-31: Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments $100.00M.
| Period end | Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments |
|---|---|
| 2017-12-31 | $100.00M 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |